These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 25736418

  • 1. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.
    J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [Abstract] [Full Text] [Related]

  • 3. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B.
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [Abstract] [Full Text] [Related]

  • 4. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 5. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
    Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F, Groth E, Larsson B, Böttcher G, Malmgren A, Kraan M, Rabe KF.
    Pulm Pharmacol Ther; 2017 Aug; 45():121-123. PubMed ID: 28549850
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R.
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [Abstract] [Full Text] [Related]

  • 10. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.
    Biochem Pharmacol; 2004 Nov 15; 68(10):1947-55. PubMed ID: 15476666
    [Abstract] [Full Text] [Related]

  • 11. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M, Singh D.
    J Pharmacol Exp Ther; 2013 Oct 15; 347(1):173-80. PubMed ID: 23912333
    [Abstract] [Full Text] [Related]

  • 12. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
    Braber S, Overbeek SA, Koelink PJ, Henricks PA, Zaman GJ, Garssen J, Kraneveld AD, Folkerts G.
    Eur J Pharmacol; 2011 Oct 15; 668(3):443-9. PubMed ID: 21458445
    [Abstract] [Full Text] [Related]

  • 13. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
    Russo RC, Garcia CC, Teixeira MM, Amaral FA.
    Expert Rev Clin Immunol; 2014 May 15; 10(5):593-619. PubMed ID: 24678812
    [Abstract] [Full Text] [Related]

  • 14. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.
    Zhao X, Li F, Town JR, Zhang X, Wang W, Gordon JR.
    Int Immunopharmacol; 2007 Dec 15; 7(13):1723-31. PubMed ID: 17996682
    [Abstract] [Full Text] [Related]

  • 15. Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2.
    Busch-Petersen J, Carpenter DC, Burman M, Foley J, Hunsberger GE, Kilian DJ, Salmon M, Mayer RJ, Yonchuk JG, Tal-Singer R.
    J Pharmacol Exp Ther; 2017 Aug 15; 362(2):338-346. PubMed ID: 28611093
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.
    J Med Chem; 2004 Mar 11; 47(6):1319-21. PubMed ID: 14998320
    [Abstract] [Full Text] [Related]

  • 17. CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration.
    Abu Nabah YN, Losada M, Estellés R, Mateo T, Company C, Piqueras L, Lopez-Gines C, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ.
    Arterioscler Thromb Vasc Biol; 2007 Nov 11; 27(11):2370-6. PubMed ID: 17717298
    [Abstract] [Full Text] [Related]

  • 18. The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
    Uddin M, Betts C, Robinson I, Malmgren A, Humfrey C.
    Haematologica; 2017 Feb 11; 102(2):e65-e68. PubMed ID: 27742769
    [No Abstract] [Full Text] [Related]

  • 19. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.
    Eur Cytokine Netw; 2006 Mar 11; 17(1):35-41. PubMed ID: 16613761
    [Abstract] [Full Text] [Related]

  • 20. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.
    Int Immunopharmacol; 2012 Jul 11; 13(3):225-31. PubMed ID: 22561413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.